Pharmacokinetics of benzodiazepines: metabolic pathways and plasma level profiles

References

• Achtert G., Hausleiter H. J. Pharmacokinetics and biotransformation of metaclazepam. 13th CINP-Congress, Jerusalem, Israel. 1982; 2, Abstracts
   Google Scholar
• Allonen H., Ziegler G., Klotz U. Midazolam kinetics. Clin. Pharmacol. Ther. 1981; 30: 653–662
   PubMed Web of Science ®Google Scholar
• Alvan G., Odar-Cederlof I. The pharmacokinetic profile of oxazepam. Acta Psychiatr: Scand. 1978; 274: 47–55
   Google Scholar
• Alvan G., Siwers B., Vessman J. Pharmacokinetics of oxazepam in healthy volunteers. Acta Pharmacol. Toxicol. (Copenh.) 1977; 40(Suppl. 1)40–51
   PubMedGoogle Scholar
• Amrein R., Bovey F., Cano J. P., Eckert M., Ziegler W. H., Coassolo Ph., Schalch E., Burckhardt J. Pharmacokinetics and pharmacodynamics of flurazepam in man. Part II. Drugs Exp. Clin. Res. 1983; 9: 85–99
   Google Scholar
• Aucamp A. K. Aspects of pharmacokinetics and pharmacodynamics of benzodiazepines with particular reference to clobazam. Drug Dev. Res. Suppl. 1982; 1: 117–126
   Google Scholar
• Bond A., Lader M. A comparison of the psychotropic profiles of tofisopam and diazepam. Eur. J. Clin. Pharmacol. 1982; 22: 137–142
   PubMed Web of Science ®Google Scholar
• Borland R. G., Nicholson A. N. Comparison of the residual effects of two benzodiazepines (nitrazepam and flurazepam hydrochloride) and pentobarbital sodium on human performance. Br. J. Clin. Pharmacol. 1975; 2: 9–17
   PubMed Web of Science ®Google Scholar
• Breimer D. D., Danhof M. Interindividual variation in pharmacokinetics and drug metabolism. “Towards Better Safety of Drugs and Pharmaceutical Products”, D. D. Breimer. Elsevier/North Holland Biomedical Press, Amsterdam 1980; 117–142
   Google Scholar
• Breimer D. D., Jochemsen R. Pharmacokinetics of hypnotic drugs. “Psycho-pharmacology of Sleep”, D. Wheatley. Raven Press, New York 1981; 135–152
   Google Scholar
• Breimer D. D., Jochemsen R., Von Albert H.-H. Pharmacokinetics of benzodiazepines. Short-acting versus long-acting. Arzneim. Forsch. 1980; 30: 875–881
   PubMed Web of Science ®Google Scholar
• Carskadon M. A., Seidel W. F., Greenblatt D. J., Dement W. C. Daytime carry-over of triazolam and flurazepam in elderly insomniacs. Sleep 1982; 5: 361–371
   PubMed Web of Science ®Google Scholar
• Dement W., Seidel W., Carskadon M. Daytime alertness, insomnia and benzodiazepines. Sleep 1982; 5: S28–S45
   PubMed Web of Science ®Google Scholar
• Divoll Allen M., Greenblatt D. J., Arnold J. D. Single and multiple dose pharmacokinetics of estazolam, a triazolo-benzodiazepine. Psychopharmacology 1979; 66: 267–274
   PubMed Web of Science ®Google Scholar
• Divoll Allen M., Greenblatt D. J., Harmatz J. S., Shader R. I. Desmethyl-diazepam kinetics in the elderly after oral prazepam. Clin. Pharmacol. Ther. 1980; 28: 196–202
   PubMed Web of Science ®Google Scholar
• Divoll Allen M., Greenblatt D. J., Harmatz J. S., Shader R. I. Effect of age and gender on disposition of temazepam. J. Pharm. Sci. 1981; 70: 1104–1108
   PubMed Web of Science ®Google Scholar
• Eckert M., Ziegler W. H., Cano J. P., Bovey P., Amrein R., Coassola Ph., Schalch E., Burckhardt J. Pharmacokinetics and pharmacodynamics of flurazepam in man. Part I. Drugs Exp. Clin. Res. 1983; 9: 77–84
   Google Scholar
• Fabre L. F., McLendon D. M. A. A double-blind study comparing the efficacy and safety of alprazolam with imipramine and placebo in primary depression. Curr. Ther. Res. 1980; 27: 474–482
   Web of Science ®Google Scholar
• Greenblatt D. J., Allen M. D., MacLaughlin D. S., Huffman D. H., Harmatz J. S., Shader R. I. Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation. J Pharmacokin. Biopharm. 1979; 7: 159–179
   PubMedGoogle Scholar
• Greenblatt D. J., Divoll M., Abernethy D. R., Shader R. I. Benzodiazepine hypnotics: kinetic and therapeutic options. Sleep 1982; 5: S18–S27
   PubMed Web of Science ®Google Scholar
• Greenblatt D. J., Divoll M., Abernethy D. R., Moschitto L. J., Smith R. B., Shader R. I. Alprazolam kinetics in the elderly: relation to antipyrine disposition. Arch. Gen. Psychiatry 1983; 40: 287–290
   PubMed Web of Science ®Google Scholar
• Greenblatt D. J., Divoll M., Abernethy D. R., Harmatz J. S., Shader R. I. Antipyrine kinetics in the elderly-prediction of age-related changes in benzodiazepine oxidizing capacity. J. Pharmacol. Exp. Thes. 1982; 220: 120–126
   PubMed Web of Science ®Google Scholar
• Greenblatt D. J., Divoll Allen M., Harmatz J. S., Shader R. I. Diazepam disposition determinants. Clin. Pharmacol. Thes. 1980; 27: 301–312
   PubMed Web of Science ®Google Scholar
• Greenblatt D. J., Divoll M., Harmatz J. S., Shader R. I. Oxazepam kinetics: effects of age and sex. J. Pharmacol. Exp. Ther. 1980; 215: 86–91
   PubMed Web of Science ®Google Scholar
• Greenblatt D. J., Divoll M., Harmatz J. S., MacLaughlin D. S., Shader R. I. Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs. Clin. Pharmacol. Thes. 1981; 30: 475–486
   PubMed Web of Science ®Google Scholar
• Greenblatt D. J., Divoll M., Abernethy D. R., Ochs H. R., Shader R. I. Clinical pharmacokinetics of the newer benzodiazepines. Clin. Pharmacokin. 1983; 8: 233–252
   PubMed Web of Science ®Google Scholar
• Greenblatt D. J., Divoll M., Abernethy D. R., Ochs H. R., Shader R. I. Benzodiazepine kinetics. Implications for therapeutics and pharmacogeriatrics. Drug Metab. Rev. 1983; 14: 251–292
   PubMed Web of Science ®Google Scholar
• Greenblatt D. J., Divoll M., Puri S. K., Ho I., Zinny M. A., Shader R. I. Clobazam kinetics in the elderly. Br. J. Clin. Pharmacol. 1981; 12: 631–636
   PubMed Web of Science ®Google Scholar
• Greenblatt D. J., Shader R. I. Effects of age and other drugs on benzodiazepine kinetics. Arzneim. Forsch. 1980; 30: 886–890
   PubMed Web of Science ®Google Scholar
• Greenblatt D. J., Shader R. I., Divoll M., Harmatz J. S. Benzodiazepines: a summary of pharmacokinetic properties. Br. J. Clin. Pharmacol. 1981; 11: 11S–16S
   PubMed Web of Science ®Google Scholar
• Hailey D. M., Baird E. S. Plasma concentrations of medazepam and its metabolites after oral administration. Br. J. Anaesth. 1979; 51: 493–496
   PubMed Web of Science ®Google Scholar
• Hindmarch I., Clyde C. A. The effects of triazolam and nitrazepam on sleep quality, morning vigilance and psychomotor performance. Arzneim. Forsch. 1980; 30: 1163–1166
   PubMed Web of Science ®Google Scholar
• Hümpel M., Nieuweboer B., Milius W., Hanke H., Wendt H. Kinetics and biotransformation of lormetazepam. II. Radioimmunological determinations in plasma and urine of young and elderly subjects: first-pass effect. Clin. Pharmacol. Thes. 1980; 28: 673–679
   PubMed Web of Science ®Google Scholar
• Jochemsen R. Clinical pharmacokinetics of benzodiazepine hypnotics. University of Leiden, The Netherlands 1983, Ph.D. Thesis
   Google Scholar
• Jochemsen R., Van der Graaff M., Boeijinga J. K., Breimer D. D. Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. Br. J. Clin. Pharmacol. 1982; 13: 319–324
   PubMed Web of Science ®Google Scholar
• Jochemsen R., Hogendoorn J. J. H., Dingemanse J., Hermans J., Boeijinga J. K., Breimer D. D. Pharmacokinetics and bioavailability of intravenous, oral and rectal nitrazepam in humans. J. Pharmacokin. Biopharm. 1982; 10: 231–245
   PubMedGoogle Scholar
• Jochemsen R., Van Beusekom B. R., Spoelstra P., Janssens A. R., Breimer D. D. Effect of age and liver cirrhosis on the pharmacokinetics of nitrazepam. Br. J. Clin. Pharmacol. 1983; 15: 295–303
   PubMed Web of Science ®Google Scholar
• Jochemsen R., Joeres R. P., Wesselman J. G. J., Richter E., Breimer D. D. Pharmacokinetics of oral brotizolam in patients with liver cirrhosis. Br. J. Clin. Pharmacol. 1983, In press
   Google Scholar
• Jochemsen R., Nandi K. L., Corless D., Breimer D. D. Pharmacokinetics of brotizolam in the elderly. Br. J. Clin. Pharmacol. 1983, In press
   Google Scholar
• Jochemsen R., Wesselman J. G. J., Van Boxtel C. J., Hermans J., Breimer D. D. Comparative pharmacokinetics of brotizolam and triazolam in healthy subjects. Br. J. Clin. Pharmacol. 1983, In press
   Web of Science ®Google Scholar
• Jochemsen R., Van Boxtel C. J., Hermans J., Breimer D. D. Pharmacokinetics of 5 benzodiazepine hypnotics in the same panel of healthy subjects. Clin. Pharmacol. Ther. 1983, In press
   PubMed Web of Science ®Google Scholar
• Jochemsen R., Van Rijn P. A., Hazelzet T. G. M., Breimer D. D. Assay of midazolam and brotizolam in plasma by a gas chromatographic and a radioreceptor technique. Pharm. Weekbl. Sci. Ed. 1983, In press
   PubMedGoogle Scholar
• Kales A., Scharf M. B., Bixler E. O., Schweitzer P. K., Jacoby J. A., Soldatos C. R. Dose-response studies of quazepam. Clin. Pharmacol. Thea 1981; 30: 194–200
   PubMed Web of Science ®Google Scholar
• Kales A., Soldatos C. R., Bixler E. O., Kales J. D. Early morning insomnia with rapidly eliminated benzodiazepines. Science 1983; 220: 95–97
   PubMed Web of Science ®Google Scholar
• Kangas L., Iisalo E., Kanto J., Lehtinen V., Pynnönen S., Ruikka J., Salminen J., Sillanpää M., Syvälathi E. Human pharmacokinetics of nitrazepam: effects of age and disease. Eur. J. Clin. Pharmacol. 1979; 15: 163–170
   PubMed Web of Science ®Google Scholar
• Kangas L., Kanto J., Pakkanen A., Mansikka M. Comparison of sedatory and anxiolytic properties of placebo, tofisopam and nitrazepam as oral premedicaments. 12th CINP-Congress, Göteborg. 1980; 197, Abstracts
   Google Scholar
• Kanto J., Kangas L., Aaltonen L., Hilke H. Effect of age on the pharmacokinetics and sedative effect of flunitrazepam. Int. J. Clin. Pharmacol. Biopharm. 1981; 19: 400–404
   Google Scholar
• Kaplan S. A., Jack M. L., Weinfeld R. E., Glover W., Weissman L., Cotler S. Biopharmaceutic and clinical pharmacokinetic profile of bromazepam. J. Pharmacokin. Biopharm. 1976; 4: 1–16
   PubMedGoogle Scholar
• Klotz U., Avant G. R., Hoyumpa A., Schenker S., Wilkinson G. R. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J. Clin. Invest. 1975; 55: 347–359
   PubMed Web of Science ®Google Scholar
• Klotz U., Müller-Seydlitz P. Altered elimination of desmethyldiazepam in the elderly. Br. J. Clin. Pharmacol. 1979; 7: 119–120
   PubMed Web of Science ®Google Scholar
• Kraus J. W., Desmond P. V., Marshall J. P., Johnson R. F., Wilkinson G. R., Schenker S. The effects of ageing and liver disease on the disposition of lorazepam in man. Clin. Pharmacol. The. 1978; 24: 411–419
   Google Scholar
• Li F-L., Achtert G. Binding properties of metaclazepam and its metabolites to benzodiazepine receptor and its pharmacology. 13th CINP-Congress, Jerusalem, Israel, 1982; 442, Abstracts
   Google Scholar
• Lader M., Melhuish A., Harris P. Residual effects of repeated doses of 0.5 and 1 mg flunitrazepam. Eur. J. Clin. Pharmacol. 1982; 23: 135–140
   PubMed Web of Science ®Google Scholar
• Lippa A. S., Meyerson L. R., Beer B. Molecular substrates of anxiety: clues from the heterogeneity of benzodiazepine receptors. Life Sci. 1982; 31: 1409–1417
   PubMed Web of Science ®Google Scholar
• Morgan K., Oswald I. Anxiety caused by a short-life hypnotic. Br. Med. J. 1962; 284: 942
   Google Scholar
• Nicholson A. N., Stone B. M. Activity of the hypnotics, flunitrazepam and triazolam, in man. Br. J. Clin. Pharmacol. 1980; 9: 533–541
   Google Scholar
• Nicholson A. N., Stone B. M., Pascoe P. Studies on sleep and performance with a triazolo-1, 4-thienodiazepine (brotizolam). Br. J. Clin. Pharmacol. 1980; 10: 75–82
   PubMed Web of Science ®Google Scholar
• Nicholson A. N., Stone B. M. Imidazo-benzodiazepines: sleep and performance studies in man. J. Clin. Psychopharmacol. 1983; 3: 72–75
   PubMedGoogle Scholar
• Pecknold J. C., McClure D. J., Fleury D., Chang H., Elie R. A controlled comparative study of halazepam in anxiety. Curr. Ther. Res. 1982; 32: 895–905
   Web of Science ®Google Scholar
• Perrier F. Bilan de l'étude coopérative du bromazepam portant stir 3401 observations de psychiatric ambulatoire et 8191 observations de médicine practicienne. Nouv. Press Méd. 1982; 11: 1747–1751
   PubMedGoogle Scholar
• Róai S., Orosz E., Bolla K. Human pharmacokinetic data on Grandaxin. Ther. Hung. 1975; 23: 139–142
   PubMedGoogle Scholar
• Ruhland M., Hell I., Muesch H. R., Rohle O. CNS-pharmacological properties of the new anxiolytic drug metaclazepam — animal studies with mice and rats. 13th CINP-Congress, Jerusalem, Israel, 1982; 632, Abstracts
   Google Scholar
• Rupp W., Badian M., Christ O., Hadju P., Kulkarni R. D., Tacuber K., Uihlein M., Bender R., Vanderbeke O. Pharmacokinetics of single and multiple doses of clobazam in humans. Br. J. Clin. Pharmacol. 1979; 7: 51S–57S
   PubMed Web of Science ®Google Scholar
• Schacht U., Baecker G. Effects of clobazam in benzodiazepine-receptor binding assays. Drug Dev. Rex. 1982, Suppl. 1: 83–93
   Google Scholar
• Schwartz H. J. Phatmacokinetics and metabolism of temazepam in man and several animal species. Br. J. Clin. Pharmacol. 1979; 8: 23S–29S
   PubMed Web of Science ®Google Scholar
• Sellers E. M., Greenblatt D. J., Giles H. G., Naranjo C. A., Kaplan H., MacLeod S. M. Chlordiazepoxide and oxazepam disposition in cirrhosis. Clin. Pharmacol. Ther. 1979; 26: 240–246
   PubMed Web of Science ®Google Scholar
• Shull H. J., Jr., Wilkinson G. R., Johnson R., Schenker S. Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann. Infern. Med. 1976; 84: 420–425
   PubMed Web of Science ®Google Scholar
• Wickstrom E., Amrein R., Haefelfinger P., Hartmann D. Pharmacokinetic and clinical observations on prolonged administration of flunitrazepam. Eur. J. Clin. Pharmacol. 1980; 17: 189–196
   PubMed Web of Science ®Google Scholar